FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199211105> ?p ?o ?g. }

• W3199211105 endingPage "367" @default.
• W3199211105 startingPage "364" @default.
• W3199211105 abstract "•Standard chemotherapy plus surgery yields to unsatisfying results in BRAF-mutated colorectal liver metastases (CLM). Combination of targeted agents (encorafenib, a BRAF inhibitor, and cetuximab, an anti-EGFR) is the new standard of care for BRAF V600E-mutated mCRC refractory to a first-line standard chemotherapy. Up to now no evidence is available concerning the activity of this novel treatment as conversion therapy in CLM setting. •Our case provides evidence, for the first time to our knowledge, of the activity of encorafenib plus cetuximab as conversion regimen for BRAF V600E-mutated CLM. Additional observations in this case report concern mechanisms underlying rapid occurrence of acquired resistance and the role of CEA serum levels as biomarker to monitor treatment activity and occurrence of resistance, allowing to optimize the timing of surgery. •Further evidence on the role of doublet targeted regimen (encorafenib plus cetuximab) as conversion treatment in the setting of BRAF-mutant CLM is warranted. •Standard chemotherapy plus surgery yields to unsatisfying results in BRAF-mutated colorectal liver metastases (CLM). Combination of targeted agents (encorafenib, a BRAF inhibitor, and cetuximab, an anti-EGFR) is the new standard of care for BRAF V600E-mutated mCRC refractory to a first-line standard chemotherapy. Up to now no evidence is available concerning the activity of this novel treatment as conversion therapy in CLM setting. •Our case provides evidence, for the first time to our knowledge, of the activity of encorafenib plus cetuximab as conversion regimen for BRAF V600E-mutated CLM. Additional observations in this case report concern mechanisms underlying rapid occurrence of acquired resistance and the role of CEA serum levels as biomarker to monitor treatment activity and occurrence of resistance, allowing to optimize the timing of surgery. •Further evidence on the role of doublet targeted regimen (encorafenib plus cetuximab) as conversion treatment in the setting of BRAF-mutant CLM is warranted." @default.
• W3199211105 created "2021-09-27" @default.
• W3199211105 creator A5000969455 @default.
• W3199211105 creator A5008175617 @default.
• W3199211105 creator A5016773277 @default.
• W3199211105 creator A5026474135 @default.
• W3199211105 creator A5026748433 @default.
• W3199211105 creator A5032909786 @default.
• W3199211105 creator A5033675152 @default.
• W3199211105 creator A5037327785 @default.
• W3199211105 creator A5043302833 @default.
• W3199211105 creator A5043712728 @default.
• W3199211105 creator A5048039634 @default.
• W3199211105 creator A5050215401 @default.
• W3199211105 creator A5056406078 @default.
• W3199211105 creator A5073553980 @default.
• W3199211105 creator A5074681974 @default.
• W3199211105 creator A5080802426 @default.
• W3199211105 date "2021-12-01" @default.
• W3199211105 modified "2023-10-16" @default.
• W3199211105 title "Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report" @default.
• W3199211105 cites W1586939666 @default.
• W3199211105 cites W1984919087 @default.
• W3199211105 cites W2072276422 @default.
• W3199211105 cites W2135454464 @default.
• W3199211105 cites W2135800465 @default.
• W3199211105 cites W2183840686 @default.
• W3199211105 cites W2225497209 @default.
• W3199211105 cites W2234830428 @default.
• W3199211105 cites W2301065828 @default.
• W3199211105 cites W2561040446 @default.
• W3199211105 cites W2561667833 @default.
• W3199211105 cites W2582131355 @default.
• W3199211105 cites W2603299281 @default.
• W3199211105 cites W2761998606 @default.
• W3199211105 cites W2791410762 @default.
• W3199211105 cites W2803281998 @default.
• W3199211105 cites W2883420771 @default.
• W3199211105 cites W2916085177 @default.
• W3199211105 cites W2952880572 @default.
• W3199211105 cites W2962862457 @default.
• W3199211105 cites W2977895282 @default.
• W3199211105 cites W3040757981 @default.
• W3199211105 cites W3041320895 @default.
• W3199211105 cites W3123642801 @default.
• W3199211105 cites W3153990830 @default.
• W3199211105 doi "https://doi.org/10.1016/j.clcc.2021.09.002" @default.
• W3199211105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34629317" @default.
• W3199211105 hasPublicationYear "2021" @default.
• W3199211105 type Work @default.
• W3199211105 sameAs 3199211105 @default.
• W3199211105 citedByCount "2" @default.
• W3199211105 countsByYear W31992111052022 @default.
• W3199211105 countsByYear W31992111052023 @default.
• W3199211105 crossrefType "journal-article" @default.
• W3199211105 hasAuthorship W3199211105A5000969455 @default.
• W3199211105 hasAuthorship W3199211105A5008175617 @default.
• W3199211105 hasAuthorship W3199211105A5016773277 @default.
• W3199211105 hasAuthorship W3199211105A5026474135 @default.
• W3199211105 hasAuthorship W3199211105A5026748433 @default.
• W3199211105 hasAuthorship W3199211105A5032909786 @default.
• W3199211105 hasAuthorship W3199211105A5033675152 @default.
• W3199211105 hasAuthorship W3199211105A5037327785 @default.
• W3199211105 hasAuthorship W3199211105A5043302833 @default.
• W3199211105 hasAuthorship W3199211105A5043712728 @default.
• W3199211105 hasAuthorship W3199211105A5048039634 @default.
• W3199211105 hasAuthorship W3199211105A5050215401 @default.
• W3199211105 hasAuthorship W3199211105A5056406078 @default.
• W3199211105 hasAuthorship W3199211105A5073553980 @default.
• W3199211105 hasAuthorship W3199211105A5074681974 @default.
• W3199211105 hasAuthorship W3199211105A5080802426 @default.
• W3199211105 hasConcept C121332964 @default.
• W3199211105 hasConcept C121608353 @default.
• W3199211105 hasConcept C126322002 @default.
• W3199211105 hasConcept C142424586 @default.
• W3199211105 hasConcept C143998085 @default.
• W3199211105 hasConcept C2779013556 @default.
• W3199211105 hasConcept C2779998722 @default.
• W3199211105 hasConcept C2781230642 @default.
• W3199211105 hasConcept C2781413609 @default.
• W3199211105 hasConcept C502942594 @default.
• W3199211105 hasConcept C526805850 @default.
• W3199211105 hasConcept C71924100 @default.
• W3199211105 hasConcept C87355193 @default.
• W3199211105 hasConceptScore W3199211105C121332964 @default.
• W3199211105 hasConceptScore W3199211105C121608353 @default.
• W3199211105 hasConceptScore W3199211105C126322002 @default.
• W3199211105 hasConceptScore W3199211105C142424586 @default.
• W3199211105 hasConceptScore W3199211105C143998085 @default.
• W3199211105 hasConceptScore W3199211105C2779013556 @default.
• W3199211105 hasConceptScore W3199211105C2779998722 @default.
• W3199211105 hasConceptScore W3199211105C2781230642 @default.
• W3199211105 hasConceptScore W3199211105C2781413609 @default.
• W3199211105 hasConceptScore W3199211105C502942594 @default.
• W3199211105 hasConceptScore W3199211105C526805850 @default.
• W3199211105 hasConceptScore W3199211105C71924100 @default.
• W3199211105 hasConceptScore W3199211105C87355193 @default.
• W3199211105 hasIssue "4" @default.

• next